Tirzepatide Plus, administered once weekly, comprises a unique combination of GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonists, representing a novel therapeutic approach studied for obesity treatment. Cyanocobalamin (B12) supplementation is incorporated to enhance energy levels. GIP aids in reducing food intake and increasing energy expenditure, resulting in weight reduction.

When combined with a GLP-1 receptor agonist, Tirzepatide Plus yields significant effects on glucose regulation, weight loss, A1C reduction, and improvements in cardiometabolic measures, while also curbing appetite. Tirzepatide/Semaglutide injections signal satiety to the brain, facilitating reduced food intake, and slow gastric emptying, prolonging the feeling of fullness. Eligibility for the weight loss program requires a BMI >30 or >27 with at least one comorbidity.

Semaglutide is complemented with L-carnitine, promoting fat metabolism, while Tirzepatide is paired with B12 for enhanced energy levels.